Intensifying approaches to address clinical inertia among cardiovascular disease risk factors: A narrative review
- PMID: 36002348
- PMCID: PMC9675717
- DOI: 10.1016/j.pec.2022.08.005
Intensifying approaches to address clinical inertia among cardiovascular disease risk factors: A narrative review
Abstract
Objective: Clinical inertia, the absence of treatment initiation or intensification for patients not achieving evidence-based therapeutic goals, is a primary contributor to poor clinical outcomes. Effectively combating clinical inertia requires coordinated action on the part of multiple representatives including patients, clinicians, health systems, and the pharmaceutical industry. Despite intervention attempts by these representatives, barriers to overcoming clinical inertia in cardiovascular disease (CVD) risk factor control remain.
Methods: We conducted a narrative literature review to identify individual-level and multifactorial interventions that have been successful in addressing clinical inertia.
Results: Effective interventions included dynamic forms of patient and clinician education, monitoring of real-time patient data to facilitate shared decision-making, or a combination of these approaches. Based on findings, we describe three possible multi-level approaches to counter clinical inertia - a collaborative approach to clinician training, use of a population health manager, and use of electronic monitoring and reminder devices.
Conclusion: To reduce clinical inertia and achieve optimal CVD risk factor control, interventions should consider the role of multiple representatives, be feasible for implementation in healthcare systems, and be flexible for an individual patient's adherence needs.
Practice implications: Representatives (e.g., patients, clinicians, health systems, and the pharmaceutical industry) could consider approaches to identify and monitor non-adherence to address clinical inertia.
Keywords: Cardiovascular disease; Clinical inertia; Diabetes mellitus; Disease management; Medication adherence; Treatment outcome.
Published by Elsevier B.V.
Conflict of interest statement
Competing interests Dr. Zullig reports research grant support from the PhRMA Foundation, and Proteus Digital Health and consulting from Novartis and Pfizer. Dr. Lewinski reports research support from PhRMA Foundation and Otsuka. Drs. Goldstein and Jazowski report no conflicts of interest. Dr. Bosworth reports research grants from Sanofi, PhRMA Foundation, Proteus Digital Health, Otsuka, Novo Nordisk, Improved Patient Outcomes, Boehringer Ingelheim as well as consulting from Otsuka, Abbott, Walmart, Better therapeutics, VIDYA, and Sanofi.
Figures
Similar articles
-
Clinical Inertia in a Randomized Trial of Telemedicine-Based Chronic Disease Management: Lessons Learned.Telemed J E Health. 2018 Oct;24(10):742-748. doi: 10.1089/tmj.2017.0184. Epub 2018 Jan 17. Telemed J E Health. 2018. PMID: 29341850 Clinical Trial.
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
-
Clinical inertia, reverse clinical inertia, and medication non-adherence in type 2 diabetes.J Endocrinol Invest. 2019 May;42(5):495-503. doi: 10.1007/s40618-018-0951-8. Epub 2018 Oct 6. J Endocrinol Invest. 2019. PMID: 30291589 Review.
-
Therapeutic inertia.Aust Prescr. 2024 Feb;47(1):15-19. doi: 10.18773/austprescr.2024.001. Aust Prescr. 2024. PMID: 38444892 Free PMC article. Review.
Cited by
-
Vascular medicine in the 21st century: Embracing comprehensive vasculature evaluation and multidisciplinary treatment.World J Clin Cases. 2024 Sep 26;12(27):6032-6044. doi: 10.12998/wjcc.v12.i27.6032. World J Clin Cases. 2024. PMID: 39328850 Free PMC article. Review.
-
Validation of the Novel Web-Based Application HUMTELEMED for a Comprehensive Assessment of Cardiovascular Risk Based on the 2021 European Society of Cardiology Guidelines.J Clin Med. 2024 Apr 16;13(8):2295. doi: 10.3390/jcm13082295. J Clin Med. 2024. PMID: 38673568 Free PMC article.
-
Exploring primary care physicians' challenges in using home blood pressure monitoring to manage hypertension in Singapore: a qualitative study.Front Med (Lausanne). 2024 Mar 25;11:1343387. doi: 10.3389/fmed.2024.1343387. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38590317 Free PMC article.
-
Therapeutic inertia in the management of neuromyelitis optica spectrum disorder.Front Neurol. 2024 Feb 21;15:1341473. doi: 10.3389/fneur.2024.1341473. eCollection 2024. Front Neurol. 2024. PMID: 38450077 Free PMC article.
-
World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease: 2023 Update.Glob Heart. 2024 Jan 22;19(1):8. doi: 10.5334/gh.1278. eCollection 2024. Glob Heart. 2024. PMID: 38273995 Free PMC article.
References
-
- DiMatteo MR. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Medical care. 2004;42(3):200–209. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
